Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC312 in refractory autoimmune diseases
NCT06888960Phase 1Recruiting
- Sponsor
- CytoCares
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CC312 in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc) and 3 more, sponsored by CytoCares. Primary endpoints: Dose-Limiting Toxicity at 2 years and Adverse Events/Serious Adverse Events at 2 years. Started Nov 2024; status: recruiting.
02
Drugs
CC312
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathy (IIM)systemic sclerosis (SSc)rheumatoid arthritis (RA)primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06888960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888960.